Loyola University
Also known as: Bital Savir-Baruch | Cardinal Bernardin Cancer Center, Loyola University | Department Anesthesiology Loyola University Medical Center | Elizabeth Henry | Loyola Medical Center | Loyola Univeristy Medical Center | Loyola Univerity Medical Center | Loyola University | Loyola University Cardinal Bernadin Cancer Center | Loyola University Cardinal Bernardin Cancer Center | Loyola University Chicago | Loyola University Chicago Health Sciences Division | Loyola University Health System | Loyola University Medical Center | Loyola University Medical Center, Department of Surgery | Loyola University Medical Center (LUMC) | Loyola University Medical Center, Maywood, IL | Loyola Univ Med Cntr- | Loyola Univ Med Cntr - Cardinal Bernardin Cancer Cntr | Loyola Univ Med Cntr - Dept of Urology & Obstetrics/Gynecology | Marsha Ma | Patrick Stiff | Steven Edelstein
Highest phase reached
Phase 4
First clinical trial
May 1, 1989Last known activity
Nov 3, 2025
Timeline
1870s
- Jan 1, 1870
Loyola University— Founded
Drugs by trial phase (157 distinct, 115 trials)
Phase 4 (40 own, 0 via acquisition)
Phase 3 (37 own, 0 via acquisition)
Phase 2 (63 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Other trials (11 own, 0 via acquisition)
Indications
Studied for
- Acute Pain
- Anemia, Sickle Cell
- Atherosclerosis
- Bipolar Disorder
- Blood Loss, Surgical
- Brain Injuries
- Brain Injuries, Traumatic
- Breast Neoplasms
- Burns
- Calcinosis
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Cerebral Hemorrhage
- Coronary Artery Disease
- Delayed Graft Function
- Delirium
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Disease
- Endometrial Neoplasms
- Enuresis
- Fractures, Bone
- Headache
- Heart Failure
- Hemorrhage
- Hepatic Veno-Occlusive Disease
- Hip Fractures
- Hodgkin Disease
- Hypercalcemia
- Hypotension
- Ileus
- Infertility
- Inflammation
- Ischemia
- Kidney Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphangioleiomyomatosis
- Lymphoma
- Lymphoma, AIDS-Related
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Non-Hodgkin
- Major Depressive Disorder
- Melanoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myocardial Ischemia
- Nausea
- Neoplasms
- Neoplasms, Plasma Cell
- Nocturia
- Osteomyelitis
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Pelvic Girdle Pain
- Peripheral Nervous System Diseases
- Plasmacytoma
- Polyneuropathies
- Postoperative Pain
- Postpartum Hemorrhage
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Psoriasis
- Renal Insufficiency
- Seizures
- Shock
- Shock, Cardiogenic
- Small Fiber Neuropathy
- Squamous Cell Carcinoma of Head and Neck
- Stevens-Johnson Syndrome
- Syndrome
- Tachycardia
- Tachycardia, Ventricular
- Thromboembolism
- Urinary Bladder, Overactive
- Urinary Incontinence
- Urinary Incontinence, Urge
- Venous Thromboembolism
- Vitamin D Deficiency
- Vomiting
- Wounds and Injuries
Recent trials (50)
- NCT07216664Lead sponsorN/ANov 3, 2025
- NCT07216664OfficialN/ANov 3, 2025
- NCT07308808CollaboratorEarly Phase 1Sep 9, 2025
- NCT06619301Sponsor investigatorPhase 3Apr 1, 2024
- NCT06619301OfficialPhase 3Apr 1, 2024
- NCT06619301Lead sponsorPhase 3Apr 1, 2024
- NCT05983276Lead sponsorPhase 2Aug 28, 2023
- NCT05983276Overall official - principal investigatorPhase 2Aug 28, 2023
- NCT05983276Reponsible party - principal investigatorPhase 2Aug 28, 2023
- NCT05824832Lead sponsorPhase 4Feb 28, 2023
- NCT05824832Reponsible party - principal investigatorPhase 4Feb 28, 2023
- NCT05824832Overall official - principal investigatorPhase 4Feb 28, 2023
- NCT05554068Reponsible party - principal investigatorPhase 2Nov 1, 2022
- NCT05554068Lead sponsorPhase 2Nov 1, 2022
- NCT05557279Overall official - principal investigatorPhase 4Oct 1, 2022
Details
- Founded
- Chicago, IL, US Jan 1, 1870
- Last known activity
- Nov 3, 2025